HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Ferretti, G. Articles by Cognetti, F. Search for Related Content PubMed PubMed Citation Articles by Ferretti, G. Articles by Cognetti, F.

Is Recurrent Venous Thromboembolism After Therapy Reduced by Low-Molecular-Weight Heparin Compared With Oral Anticoagulants?^*

^* From the Department of Medical Oncology (Drs. Ferretti, Bria, Carlini, Felici, Papaldo, Fabi, Ciccarese, Cuppone, Cecere, Nuzzo, Terzoli, and Cognetti), Regina Elena Cancer Institute, Rome; Biostatistics Unit (Dr. Giannarelli), Regina Elena Cancer Institute, Rome; and Division of Medical Oncology (Dr. Mandalà), Treviglio Hospital, Treviglio, Italy.

Correspondence to: Gianluigi Ferretti, MD, PhD, Division of Medical Oncology "A", Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy; e-mail gia.fer{at}flashnet.it

Abstract

Purpose: To evaluate whether the incidence of recurrent venous thromboembolism (VTE) events after therapy differs for patients treated with long-term low-molecular-weight heparin (LMWH) or oral anticoagulant therapy (OAT).

Methods: All randomized studies were searched through computerized queries of MEDLINE, the Cochrane Controlled Trials Register, the American Society of Hematology abstract database, and the American Society of Clinical Oncology abstract database.

Results: Eleven studies including 2,907 patients were identified. Seven studies evaluated a period of 3 to 9 months after cessation of the allocated treatment: 5.4% of patients in the LMWH group vs 4% in the arm allocated to OAT had an episode of recurrent symptomatic VTE. Combined analysis showed a nonsignificant trend in lowering recurrent symptomatic VTE in favor of OAT (relative risk [RR], 1.29; 95% confidence interval [CI], 0.82 to 2.02; p = 0.27). By contrast, during active treatment, a statistically significant reduction of the risk of recurrent symptomatic VTE in favor of LMWH over OAT was registered (RR, 0.63; 95% CI, 0.47 to 0.83; p = 0.001). Regarding cancer patients only, 37 of 569 patients (6.5%) in the LMWH group had recurrent symptomatic VTE vs 69 of 546 patients (12.6%) in the OAT group, with a statistically significant reduction of the risk of recurrent symptomatic VTE in favor of LMWH (RR, 0.52; 95% CI, 0.35 to 0.76; p = 0.001).

Conclusions: Despite the significant reduction of the risk of recurrent symptomatic VTE in favor of LMWH over OAT during treatment, patients treated with long-term LMWH do not seem to have more frequently recurrent VTE events compared with OAT after cessation of therapy. The significant difference favoring LMWH over OAT among all patients receiving treatment comes mostly from studies enrolling cancer patients.

Key Words: deep vein thrombosis • low-molecular-weight heparin • oral anticoagulant therapy • venous thromboembolism • vitamin k antagonists

This article has been cited by other articles:

				J. F. Collen, J. L. Jackson, A. F. Shorr, and L. K. Moores Prevention of Venous Thromboembolism in Neurosurgery: A Metaanalysis Chest, August 1, 2008; 134(2): 237 - 249. [Abstract] [Full Text] [PDF]